Published by Ministry of Health, Labour and Welfare

3

Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions Linagliptin

October 17, 2017

Non-proprietary name

Linagliptin

Safety measure

Precautions should be revised in the package insert.

In the Clinically Significant Adverse Reactions subsection of the Adverse Reactions section, the following text should be added (underlined parts are revised):

Interstitial pneumonia:

Interstitial pneumonia may occur. If cough, dyspnoea, pyrexia, abnormal chest sound (crepitations), etc. are observed, examinations including chest X-ray, chest CT scan, and serum marker test should be performed immediately. If interstitial pneumonia is suspected, administration of this drug should be discontinued, and appropriate measures including administration of corticosteroids should be taken.

> Pharmaceuticals and Medical Devices Agency Office of Safety I 3·3·2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>